What question did this study set out to answer?

January 17, 2026Open Forum Infectious Diseases0 citationsOpen Access

Effectiveness and Durability of the BNT162b2 KP.2 vaccine against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults

STSara Y. TartofKaiser Permanente TFTimothy B. FranklandHawaii Department of Health JSJ.M. SlezakKaiser Permanente

Key Points

The study aims to evaluate the effectiveness and durability of the BNT162b2 KP.2 vaccine against COVID-19 related hospitalizations and emergency encounters.
Observed the effectiveness of the BNT162b2 KP.2 vaccine in adults.
Evaluated hospitalization rates and emergency department visits.
Compared outcomes against those unvaccinated with KP.2 within three months of vaccination.
Vaccine effectiveness against hospitalization was 49%.
Vaccine effectiveness against emergency department encounters was 45%.
Protection lasted more than 90 days, with some waning of effectiveness noted.

Abstract

Abstract Vaccine effectiveness (VE) of BNT162b2 KP.2 vaccine against COVID-19 hospital admissions was 49% 95%CI:30–63) and 45% (95%CI:35–54) against ED/UC encounters (versus no KP.2 vaccine at 3 months). Protection persisted 90 days from vaccination with some waning. VE remained high regardless of prior COVID-19 vaccination and among older adults.

Ask AI

Helpful

Bookmark

View Full Paper